WO2007073706A2 - Péptidos miméticos de carbohidratos y su empleo en formulaciones farmacéuticas - Google Patents
Péptidos miméticos de carbohidratos y su empleo en formulaciones farmacéuticas Download PDFInfo
- Publication number
- WO2007073706A2 WO2007073706A2 PCT/CU2006/000020 CU2006000020W WO2007073706A2 WO 2007073706 A2 WO2007073706 A2 WO 2007073706A2 CU 2006000020 W CU2006000020 W CU 2006000020W WO 2007073706 A2 WO2007073706 A2 WO 2007073706A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptides
- polysaccharide
- seq
- peptide
- nmgbps
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 212
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 121
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 161
- 239000005017 polysaccharide Substances 0.000 claims abstract description 161
- 150000004676 glycans Chemical class 0.000 claims abstract description 94
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract description 27
- 239000000427 antigen Substances 0.000 claims abstract description 23
- 102000036639 antigens Human genes 0.000 claims abstract description 23
- 108091007433 antigens Proteins 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 230000028993 immune response Effects 0.000 claims abstract description 15
- 230000001681 protective effect Effects 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 238000009472 formulation Methods 0.000 claims abstract description 11
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 10
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 9
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 claims abstract description 4
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 235000018102 proteins Nutrition 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 235000013930 proline Nutrition 0.000 claims 1
- 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 46
- 241000282414 Homo sapiens Species 0.000 abstract description 20
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 abstract description 14
- 230000005847 immunogenicity Effects 0.000 abstract description 11
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract description 9
- 238000011161 development Methods 0.000 abstract description 9
- 230000001580 bacterial effect Effects 0.000 abstract description 4
- 244000052769 pathogen Species 0.000 abstract description 4
- 230000003612 virological effect Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 description 40
- 238000002965 ELISA Methods 0.000 description 28
- 230000000844 anti-bacterial effect Effects 0.000 description 28
- 238000011160 research Methods 0.000 description 25
- 241000894006 Bacteria Species 0.000 description 23
- 241000724791 Filamentous phage Species 0.000 description 19
- 238000011156 evaluation Methods 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 230000003053 immunization Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 238000002649 immunization Methods 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 239000002775 capsule Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 108010060123 Conjugate Vaccines Proteins 0.000 description 10
- 241000588653 Neisseria Species 0.000 description 10
- 229940031670 conjugate vaccine Drugs 0.000 description 10
- 208000037941 meningococcal disease Diseases 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 108010033276 Peptide Fragments Proteins 0.000 description 6
- 102000007079 Peptide Fragments Human genes 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 229940125575 vaccine candidate Drugs 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 5
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- -1 N-substituted neuraminic acid Chemical group 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 101710176384 Peptide 1 Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- AZXKALLRCOCGBV-UHFFFAOYSA-N 1-phenyl-2-(propan-2-ylamino)hexan-1-one Chemical compound CCCCC(NC(C)C)C(=O)C1=CC=CC=C1 AZXKALLRCOCGBV-UHFFFAOYSA-N 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000006054 immunological memory Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229940035102 meningococcal group b vaccine Drugs 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229940031937 polysaccharide vaccine Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000617590 Escherichia coli K1 Species 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 241000588630 Moraxella nonliquefaciens Species 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000003918 fraction a Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012768 mass vaccination Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002887 multiple sequence alignment Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 238000000846 Bartlett's test Methods 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010027249 Meningitis meningococcal Diseases 0.000 description 1
- 201000010924 Meningococcal meningitis Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241000287798 Neisseria meningitidis CU385 Species 0.000 description 1
- 241000921898 Neisseria meningitidis serogroup A Species 0.000 description 1
- 108700018753 Neisseria porin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 101900205473 Plasmodium falciparum Circumsporozoite protein Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000001188 anti-phage Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000030499 combat disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 229940124731 meningococcal vaccine Drugs 0.000 description 1
- 229960005037 meningococcal vaccines Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention is related to the branch of medicine, particularly with the development of new vaccine formulations, of preventive or therapeutic application, which allow inducing or increasing the immune response against specific antigens to combat diseases of diverse origin.
- Prior art is related to the branch of medicine, particularly with the development of new vaccine formulations, of preventive or therapeutic application, which allow inducing or increasing the immune response against specific antigens to combat diseases of diverse origin.
- Carbohydrates with chemical structure of repeated units of N-substituted neuraminic acid, linked by ⁇ 2-8 bond, are found, for example, as constituents of the polysaccharide capsule of bacteria N. meningitidis of serogroup B.
- the polysaccharide constituting Ia This bacterium capsule is specifically constituted by repeated units of N-acetylated neuraminic acid, linked by ⁇ 2-8 bond (Bhattacharjee AK et al. 1975. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance J. Biol. Chem. 250: 1926-1932).
- Neisseria meningitidis is a Gram negative bacterium whose only host is the human being and constitutes the causative agent of the meningococcal disease. Usually this bacterium is part of the transient natural microbiota of the upper respiratory tract of healthy individuals known as carriers and this is the most common route for its microbiological isolation. Children under 2 years of age are the population most susceptible to contracting meningococcal meningitis, the most common clinical complication of meningococcal disease. However, adolescents and the elderly population can also be affected. Meningococcal disease without treatment is fatal in most affected individuals, and vaccination could prevent this situation by avoiding even early stages such as bacterial colonization. The clinical isolates of N.
- meningitidis generally have a polysaccharide capsule. Structural differences in the capsule of different isolates, which generate antigenic differences, form the basis of the classification of the bacterium in several serogroups (Rosenstein NE and Perkins BA. 2000. Update on Haemophilus influenzae serotype b and meningococcal vaccines. Pediatr. Clin. North. Am., 47: 337-352) . Of the 13 serogroups of N. meningitidis reported so far, the most important clinically are the A, B, C, Y and W-135. Serogroup A is primarily responsible for epidemics in sub-Saharan Africa. Serogroups B and C are associated with most of the cases that occur in developed countries.
- Serogroups Y and W135 are present in most of the remaining cases of the disease and infection prevalent in some regions of the United States, with a marked increase in recent years (Rosenstein N. et al. 2001. Meningococcal disease. N Engl. J. Med, 344, 1378-1388). Serogroup B is responsible for 50-70% of cases of bacterial meningitis reported in infants and children. In infected adolescents it can cause fatal sepsis (Romero JD and Outschoorn IM 1997. The immune response to the capsular polysaccharide of Neisser ⁇ a meningitidis group B. Zentralbl. Bakteriol. 285: 331-340).
- VME The outer membrane
- LOS lipooligosaccharides
- the Cuban vaccine commercially called VA-MENGOC-BC ® , manufactured from the most frequent clinical isolation of Cuba, of serological classification B: 4: P1.19,15, showed an efficiency of 83% in field studies and as a result of its massive application in Cuba the incidence of meningococcal disease decreased from 14.4 infected per 100 000 inhabitants in 1983 to 0.45 cases per 100,000 inhabitants in 1994 (Sierra GV et al. 1991. Vaccine against group B Neisseria meninqitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14: 195-207; Diaz RJ. And Outschoorn IM 1994. Current status of meningococcal group B vaccine candidates: capsular or noncapsular? Clin. Microbio !. Rev.
- conjugate vaccines allow to overcome the main difficulties associated with the use as immunogens of unconjugated polysaccharides, such as the induction of thymus-independent and short-lived immune response, the absence of stimulation of immune memory response with maturation of affinity and The generation of a phenomenon of hyporesponse, well documented in the case of serogroup C, in individuals repeatedly immunized with said vaccines, as occurs for example in areas of high incidence of the disease (Jennings H. and Lugowski C. 1981. Immunochemistry of groups A, B and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 127: 1011-1018; GoId R. and Lepow ML 1975.
- meningitidis consists of sialic acid, specifically a linear homopolymer of approximately 200 repeated units of N-acetylated neuroamine acid residues linked by ⁇ (2-8) bonds (Bhattacharjee AK et al. 1975 Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance J. Biol. Chem. 250: 1926-1932; Frosch M. and Edwards U. 1993. Molecular mechanism of capsule expression in Neisseria menin ⁇ itidis serogroup B. p 49-57 in J. Roth, U.
- Sialic acid is also found on the surface of some tissues of the human host. Homopolymers of repeated units of N-acetylated neuroamine acid residues linked by ⁇ (2-8) bonds, constitute the only glycosylation of adhesion proteins of mammalian neuronal cells (N-CAM), but unlike the capsular polysaccharide of serogroup B of N. meningitidis, the carbohydrate chains on human cells are shorter, approximately 10-50 repeated units (Chuong CM et al. 1984. Alterations in neural cell adhesion molecules dur ⁇ ng development of different regions of the nervous system. J. Neurosci. 4: 2354-2368).
- the immunization with glycoconjugates of a derivative of polysaccharide B of the menningococcus, in which the N-acetyl groups thereof were replaced by N-propionyl groups induced the production of two antibody populations: a minority, which was adsorbed with solutions of polysaccharide B purified from the bacterium, which did not show bactericidal or protective activity and a majority, which was not adsorbed to the purified polysaccharide B, characterized by being of an IgG isotype, which showed bactericidal activity against several strains of serogroup B of N Meningitidis was able to reduce or eliminate bacteremia in mice challenged with lethal doses of meningococcus and did not recognize human tissues (Jennings HJ et al.
- N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisser ⁇ a meningitidis. J Exp Med 165: 1207-1211; Jennings HJ et al. 1986. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol 137: 1708-1713; Ashton FE et al. 1989. Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide.
- Microb Pathog 6 455-458; Michon F. et al. 1987. Conformational differences between linear alpha (2 - 8) -linked homosialooligosaccharides and the epitope of the group B meningococcal polysaccharide. Biochemistry 26: 8399-8405; Put RA et al. 1997. N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in-group B Neisser ⁇ a meningitidis. J. Exp. Med. 185: 1929-1938).
- the second epitope is detectable only when the native polysaccharide retains its high molecular size and is wound in the form of a helix, as it is disposed on the surface of the bacterium.
- This second epitope of a conformational nature, is responsible for the production of bactericidal and protective antibodies, which do not recognize human tissues.
- the literature describes the isolation of monoclonal antibodies that have been grouped according to their specificity and properties in two populations that correspond exactly to those previously explained (Pon RA et al. 1997. N-Propionylated group B meningococcal polysaccharide mimics a unique Bactericidal capsular epitope In-group B Neisser ⁇ a meningitidis J. Exp. Med.
- Ia constitutes the use as Immunogens of peptide sequences that constitute specific molecular mimetics of the conformational epitope responsible for protection, present in polysaccharide B when it is in its native conformation on the surface of the bacterium.
- One of the ways to identify mimotopes of the capsular polysaccharides is through the screening, with antibodies, of libraries of peptides exposed in filamentous phages. The development of this technology is based on the ability of the filamentous phages to expose on their surface foreign peptide sequences fused to the viral capsid proteins.
- the peptide sequences exposed on the surface of the viral particle are easily accessible and potentially capable of specifically binding to the molecules used for the selection, and therefore can be selected based on said affinity.
- the sequence of a peptide from a library chosen by a certain property can be easily deduced from the nucleotide sequence of the phage that it exposes (Parmley SF et al. 1988. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73 : 305-318; Smith GP et al. 1993. Free them of peptides and proteins displayed on filamentous phage. Methods Enzymol. 217: 228-257; Cwirla SE et al. 1990.
- Peptides on phage a vast librar / of peptides for identifying ligands Proc. Nati. Acad. Sci. USA; 87: 6378-6382).
- Said peptides to be considered as possible vaccine candidates must first be able to bind specific antibodies against the original antigen, and inhibit the binding of said antibodies to said antigen and secondly they must induce an immune response characterized by the presence of antibodies that recognize the pathogen and protect against the infection caused by it.
- These peptides which are reproducible and well-defined structures, can substitute for the natural antigen in the process of making vaccines with the additional advantage that since the target of the antibodies induced by them is well defined, the possibility of inducing auto-antibodies is eliminated.
- Filamentous phage have been shown to be potent carrier proteins, capable of presenting peptides to the immune system effectively [Meóla A. e ⁇ al. 1995. Derivation of vaccines from mimotopes: Immunologic properties of human Hepatitis B virus surface antigen mimotopes displayed on filamentous phage. J. Immunol. 154: 3162-3172: de la Cruz VF e ⁇ al. 1988. Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage. J. Biol. Chem. 263: 4318-4322; Greenwood J. et al. 1991. Multiple display of foreign peptides on a filamentous bacteriophage.
- Peptide librarles defines the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans J. Mol. Biol. 261: 11-22; Harris S. L et al. 1997. Exploring the basis of peptide-carbohydrate crossreactivity: evidence for discrimination by peptides between closely related anti- carbohydrate antibodies Proc. Nati. Acad. Sci. USA 94: 2454-2459; Pincus SH ei al. 1998. Peptides that mimic the group B Streptococcal type III capsular polysaccharide antigen J. Immunol. 160: 293-298; Phalipon A ei al. 1997. Induction of anti-carbohydrate antibodies by phage library-selected pep ⁇ de mimics. Eur. J. Immunol. 27: 2620-2625).
- Granoff DM and Moe G. R in USP 6,642,354 B2 protected the use in vaccine formulations of 67 peptide sequences, which were selected from libraries of phage-exposed peptides, based on their ability to bind anti-monoclonal antibodies.
- Polysaccharide B Two of them were selected for immunological studies and for this they were synthesized and VME conjugated peptides of N. meningitidis obtained from a strain of meningococcus serogroup B, capsule mutant. In said patent they report that immunization with one of these conjugates induced the production of antibodies that showed bactericidal activity against N. meningitidis of serogroup B.
- VME bactericidal activity
- the antibodies generated by these peptides do not have cross-reactivity with the epitope formed by the short chains of polysalic acid present on certain human tissues, the possibility of leading to the triggering of an autoimmune response is eliminated. They constitute, therefore, an alternative source of antigens that allow the development of new generation reagents, of potential use in diagnosis, therapy or disease prevention.
- the peptides NMGBPS1, NMGBPS2, NMGBPS3, NMGBPS4 are reported for the first time, as components of reagents for diagnosis or of a vaccine formulation of a therapeutic or preventive nature against meningococcal disease or any infection caused by a member of the Neisseria genus or by other bacteria, viruses or parasites.
- the novel character of this invention resides in the description for the first time of peptides NMGBPS1, NMGBPS2, NMGBPS3, NMGBPS4, as molecular mimotopes of epitopes present in the capsular polysaccharide of serogroup B of Neisseria meningitidis, capable of inducing the production of bactericidal antibodies against Meningococcal strains belonging to this serogroup.
- peptides can be used as reagents for diagnosis and / or in vaccine formulations to treat or prevent the disease caused by
- FIG. 1 The phages selected after the screening with the anti-polysaccharide B monoclonal antibody, from the library of peptides exposed in phages, they were applied on a nitrocellulose membrane and faced the selector antibody. At each point 30 ⁇ g of each of the selected individual phages were applied. In G5 and 15 the control phage was applied.
- FIG. 1 Evaluation of the ELISA reactivity of the phages adsorbed to the selector antibody after the third cycle of the research carried out in the library.
- the phages were purified individually and used to coat the ELISA plates.
- the graph shows the Absorbance at 492 nm (at 492 nm) obtained in the ELISAs for 13 of the phages evaluated.
- FIG. 3 Evaluation of the reactivity by ELISA of the phages adsorbed to the selector antibody after the second cycle of the research conducted to the library.
- the phages were purified individually and used to coat the ELISA plates.
- the graph shows the Absorbance at 492 nm (at 4 g 2 nm) obtained in the ELISAs for 16 of the phages evaluated.
- FIG. 4 Evaluation of the reactivity, using 3 ELISA systems: conventional, sandwich and inhibition, as explained in the text, in Example 9, of the phages that express on their surface the peptides selected from the research of Ia library of peptides exposed in phages with the monoclonal antibody anti-polysaccharide B.
- FIG. 1 Antibody levels (IgG) induced after immunization of Balb / c mice with the NMGBPS1-NMGBPS4 peptides exposed in filamentous phages, evaluated by ELISA.
- the graph shows the increases in specific antibodies detected in the immune sera, extracted after the 3rd dose with respect to the preimmune sera, extracted before immunizations for the groups immunized with each phage.
- Figure 6 Fragments of peptides synthesized on cellulose membrane for the determination of epitopes recognized by the anti-polysaccharide B monoclonal antibody and by murine sera induced against the NMGBPS1 peptide.
- FIG. 7 Reactivity of the anti-polysaccharide B monoclonal antibody (left panel) and of the murine sera induced against the NMGBPS1 peptide (right panel) when faced with a collection of peptide fragments derived from the NMGBPS1 peptide.
- the design of the peptide fragment collection is shown in Figure 6.
- Figure 8. Collection of peptides synthesized on pins, derived from modifications introduced to the NMGBPS1 peptide consisting of a) the simultaneous replacement of Pro in positions 7 and 8 with a Wing in each position and b) introduction of 1 to 3 specific changes in Ia anti-polysaccharide B monoclonal antibody binding sequence.
- Peptide 1 corresponds to the NMGBPS1 sequence.
- Figure 9 Reactivity of the collection of peptides synthesized on pins and presented in Figure 8, when faced with the anti-polysaccharide monoclonal antibody B.
- the numbers of the peptides correspond to the list shown in Figure 8.
- Bar 1 corresponds with the reactivity with the NMGBPSl peptide
- FIG. 10 Reactivity with the anti-polysaccharide B monoclonal antibody of the peptides, based on the sequence of NMGBPS1, in which in each case Vi 2 was substituted by A (peptide 5), Vi 2 by S (peptide 11), Vi 2 by E (peptide 12), V 9 by A (peptide 16), Yn by E (peptide 14) or Yn by I (peptide 2). In all cases, P 7 and P 8 were replaced simultaneously with an A in each position. The numbers of the peptides correspond to the list shown in Figure 8. Bar 1 (peptide 7) corresponds to the reactivity with the NMGBPS1 peptide to which the P 7 and P 8 were simultaneously replaced by an A in each position . Figure 11.
- FIG. 12 Collection of peptides synthesized on pins, derived from modifications introduced to the NMGBPS1 peptide consisting of a) the replacement of Vi 2 by Ai 2 , Si 2 and Ei 2 and b) the replacement of P 7 by A 7 or P 8 by To 8 .
- Peptide 1 corresponds to the sequence of NMGBPS1 Figure 13. Reactivity of the collection of peptides synthesized on pins and presented in Figure 12 when faced with the monoclonal antibody anti-polysaccharide B.
- Figure 14 Reactivity with the anti-polysaccharide B monoclonal antibody of peptides based on the NMGBPS1 sequence (bar 1), in which modifications 1) substitution of W 10 by F 10 and 2) the substitution of P 7 by A were introduced. 7 or P 8 by AB.
- the graph shows the sequence of each peptide evaluated.
- Figure 15 Inhibition of the binding of the anti-polysaccharide B monoclonal antibody to the capsular polysaccharide of serogroup B of Neisser ⁇ a meningitidis, using as ligands a) peptide containing 3 copies of the minimum sequence necessary for the binding of the NMGBPS1 peptide to the anti-monoclonal antibody polysaccharide B; b) NMGBPS1 peptide and c) control peptide.
- Example 1 Research of the library of peptides exposed in phages with a monoclonal anti-polysaccharide B antibody from Neisser ⁇ a meningitidis.
- a library of linear peptides of 15 amino acids expressed in the P8 region of filamentous phages was constructed and the screening thereof was carried out using as a selector molecule a murine monoclonal antibody with bactericidal activity against N . serogroup B meningitidis and that does not recognize human tissues (Pon RA e ⁇ al. 1997. N-Propionylat ⁇ d group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in-group B Neisser ⁇ a meningitidis. J. Exp. Med. 185: 1929-1938 ).
- Fraction A1 was amplified and faced with anti-polysaccharide B monoclonal antibody and again the adsorbed and non-adsorbed fractions to the antibody were collected and titrated. This process in the form of cycles was repeated until the ratio N / title A gave less than 10 3 . In total, four research cycles were carried out. Table 1 shows the values obtained from the holder of fractions A and N obtained after each research cycle. The table also shows the title of fraction A obtained in each research cycle after being amplified and purified to be used in the next cycle.
- the phage adsorbed to the selector antibody after the fourth research cycle of the library were used to infect XL-1 blue cells and several dilutions were poured onto agar plates with 2XYT culture medium. Individual phage plates were selected and amplified in liquid cultures. The phages were purified by precipitation with polyethylene glycol.
- Example 2 Reactivity with the antibody selected from the selected phages after the fourth research cycle of the library.
- Example 3 Purification and sequencing of the DNA of the selected phages after the fourth research cycle of the library with the anti-polysaccharide B monoclonal antibody.
- the DNA was purified from 25 of the phages that were positive in the immunoidentification experiment and the nucleotide sequence was determined. Phage DNA purification was carried out as described (Sambrook J. et al. 1989. Molecular Cloning, a Laboratory Manual, 2nd edn, CoId Spring Harbor Laboratory Press, CoId Spring Harbor, New York, USA).
- Viral DNA sequencing was performed using the automatic sequencer ALFexpressIl (Thermo Sequenase TM Cy TM 5 Dye Terminator Kit, Amersham Biosciences) and oligonucleotides M13 / pUC Sequencing primer (-47) # 1224, New England Biolabs Inc., USA) and M13 / pUC Reverse sequencing primer (-48) # 1233, New England Biolabs Inc., USA). In all clones the same sequence was obtained, which is shown in the sequence list (No. Sequence identification: 1). The peptide corresponding to the translation of this DNA sequence into a protein sequence is shown in the sequence list (No. Sequence identification: 5).
- Example 4 Characterization of the sequence of the peptide expressed in the selected phages after the fourth research cycle of the library with the anti-polysaccharide monoclonal antibody B.
- the sequence exposed in the selected phages after the fourth research cycle of The library was aligned with other sequences of mimetic structures of the polysaccharide B of N. meningitidis reported (Shin JS et al. 2001. Monoclonal antibodies specific for Neisseria meningitidis group B polysaccharide and their peptide mimotopes. Infect. Immun. 69 : 3335-3342; Park I. et al. 2004.
- meningitidis polysaccharide B phage adsorbed to the anti-polysaccharide B antibody was evaluated by ELISA after the third cycle of the research conducted to the library.
- the phages were individually purified and used to coat ELISA plates.
- the control phage and the phage that exposes the NMGBPS1 peptide were included in the experiment.
- OPD chromogen o-phenylene diamine
- FIG. 1 shows the results obtained for several of the purified phages. Twenty corresponding phages with those that gave signals of greater intensity in the ELISA, with respect to the signal obtained for the control, were selected to continue the work.
- Example 6 Purification and sequencing of the DNA of the selected phages after the third research cycle of the library with the anti-polysaccharide B monoclonal antibody.
- Example 7 Reactivity with the antibody selected from the selected phages after the second research cycle of the library.
- the phages adsorbed to the anti-polysaccharide antibody B were evaluated by ELISA after the second cycle of the research conducted to the library.
- the phages were purified individually and used to coat ELISA plates.
- the control phage and the phage that exposes the NMGBPS1 peptide were included in the experiment.
- the anti-polysaccharide B antibody was incubated with the monoclonal antibody.
- the reactivity was revealed, after incubating with antibodies that recognize mouse IgG conjugated to the horseradish peroxidase enzyme, with a solution containing H 2 O 2 and the chromogen o-phenylene diamine (OPD). The reaction was stopped with 2.5 N sulfuric acid and A 492nm was read in an ELISA plate reader.
- OPD chromogen o-phenylene diamine
- Figure 3 shows the results obtained for several of the purified phages. Fifteen corresponding phages with those that gave signals of greater intensity in the ELISA, with respect to the control phage, were selected to continue the work.
- Example 8 Purification and sequencing of the DNA of the selected phages after the second research cycle of the library with the anti-polysaccharide B monoclonal antibody.
- Example 9 Characterization by ELISAs of the reactivity of the peptides exposed in the filamentous phages selected after the library screening. A phage that expressed each of the unique sequences identified in Example 8 was selected to conduct a more extensive study of its reactivity with the anti-polysaccharide B monoclonal antibody.
- the DNA sequences corresponding to phage NMGBPS2, NMGBPS3 and NMGBPS4 are shown in the sequence list (No. Sequence identification: 2, 3 and 4, respectively).
- the peptides corresponding to the translation of these DNA sequences to protein sequences are shown in the sequence list (No. Sequence identification: 6, 7 and 8 respectively).
- Table 2 shows the correspondence between the identified phages and the sequence identification numbers.
- sequences obtained were also characterized by a similarity search in the NCBl database using the BLASTP 2.2.10 program (Altschul SF ef al. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein data base search programs. Nucleic Acids Res. 25: 3389-3402).
- the search was subscribed to the gene and protein sequences of bacteria contained in the SwissProt databases (http://www.ebi.ac.uk/swissprot/) and NCBI (http: //www.ncbi.nlm.nih .gov /).
- the results of this procedure indicated that there were no similarities against the sequences deposited in these databases greater than 30% for NMGBPS 2 and 4 peptides, nor greater than 35% for NMGBPS3 peptide.
- an immunization scheme was designed in Balb / c mice, in which the animals were inoculated directly with the phages exhibiting said peptides.
- the phages were purified by cesium chloride gradients, following a modification of the purification procedure 1 (Lin TC e ⁇ al. 1980. Isolation and characterization of the C and D proteins coded by gene IX and gene Vl in the filamentous bacteriophage fl and fd J. Biol. Chem. 255: 10331-10337), described by de la Cruz et al. (De la Cruz FV ef al. 1988. Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage. J. Biol. Chem. 25: 4318-4322).
- mice A group of 7 Balb / c mice (H-2 d , female sex, 7-8 weeks of age) was immunized with each phage. 10 11 viral particles were administered per mouse in each inoculation.
- a group of mice was immunized with 5 ug per mouse in each inoculation of N-propionylated N meningitidis B polysaccharide (pPSC-B) (Jennings HJ et al. 1986. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharidetetanus toxoid conjugate vaccine.
- pPSC-B N-propionylated N meningitidis B polysaccharide
- HSA human serum albumin protein
- Antibody levels (IgG) induced by NMGBPS1-NMGBPS4 peptides exposed in filamentous phage were evaluated by ELISA.
- the sera of the animals, obtained after the third inoculation, were evaluated using synthetic peptides with coating antigens. the sequences of the identified peptides.
- Figure 5 shows that the levels of specific IgG antibodies against the peptides exposed in the phages, after three immunizations with them increased significantly.
- the non-parametric method of analysis of variance of simple classification by ranges of Kruskal-Wallis was used, because the variances between the groups were not homogeneous according to the Bartlett Test. To make the multiple non-parametric comparisons, the Dunns test was performed.
- Example 13 Evaluation by bactericidal activity of the antibodies induced by the peptides selected from the screening of the library of peptides exposed in phages with the anti-polysaccharide B monoclonal antibody.
- Serum mixtures of mice from each group inoculated with each immunogen were evaluated by bactericidal activity assay.
- the test used by Ashton et al. Ashton FE et al. 1989. Protective efficacy ofmouse serum to the N-propionyl derivative of meningococcal group B polysaccharide. Microb. Pathog. 6: 455-458) was applied for the evaluation of targeted antibodies against meningococcal B polysaccharide, but instead of using the buffer solution recommended by these researchers, Veronal solution supplemented with BSA was used, which is recommended to increase the sensitivity of the bactericidal activity assay when antibodies directed against serogroup B of N are evaluated.
- Meningitidis (Mandrell RE et al. 1995. Complement-mediated bactericidal activity of human antibodies to poly alpha 2-> 8 N-acetylneuraminic acid, the capsular polysaccharide of Neisser ⁇ a menin ⁇ itidis serogroup BJ Infec ⁇ . Dis. 172: 1279-1289).
- the bactericidal antibody titer was expressed as the reciprocal of the highest antibody dilution evaluated, capable of killing at least 50% of the bacteria. Table 4 shows the results of the evaluation.
- Example 14 Mapping of the regions of the peptides recognized by the anti-polysaccharide B monoclonal antibody and by murine sera.
- Figure 7 shows the results obtained by incubating the cellulose membrane with the anti-polysaccharide monoclonal antibody B.
- the anti-polysaccharide monoclonal antibody B Of the 5 amino acid peptides, those corresponding to the VWYVE and WYVEG sequences were recognized. This result and the analysis of the reactivity pattern obtained with the rest of the peptides allows us to conclude that the minimum sequence within the NMGBPS1 peptide, necessary for the binding of the anti-polysaccharide B monoclonal antibody is the WYVE tetrapeptide.
- Figure 7 shows that when performing a similar experiment, but incubating the collection of peptides synthesized on paper with a mixture of the sera from mice immunized with the NMGBPS1 peptide exposed on filamentous phage, recognition of the peptide fragment with the WYVEG sequence was obtained, which corresponds to the results obtained for the monoclonal antibody.
- the points corresponding to the RPPVW and PPVWY sequence peptide fragments were also recognized by the mixture of the sera, which indicated the formation of a second epitope in the NMGBPS1 peptide, capable of inducing the production of antibodies.
- Example 15 Synthesis of peptide collections in which point mutations are introduced to the NMGBPS1-4 peptides and reactivity with the anti-polysaccharide B monoclonal antibody.
- Figure 8 shows the collection of synthesized peptides for the optimization of the NMGBPS1 peptide.
- Peptide 1 corresponds to the sequence of NMGBPS1.
- the Pro of positions 7 and 8 were simultaneously replaced by Ala in both positions.
- positions corresponding to amino acids necessary for the binding of the anti-polysaccharide B antibody were introduced from one to three specific changes, taking into account the criteria explained in the previous paragraph.
- Figure 9 shows the reactivity obtained when facing the collection of peptides shown in Figure 8 to the anti-polysaccharide monoclonal antibody B.
- Figure 12 shows the second collection of peptides that were synthesized to continue optimizing the sequence of the NMGBPS1 peptide.
- Sequence 1 corresponds to the NMGBPS1 peptide.
- Peptides were synthesized in which the binding sequence of the anti-polysaccharide B antibody only contained changes in V 12 by Ai 2 , Si 2 and Ei 2 and each of these peptide variants was synthesized containing in turn changes in any of the P for A.
- similar peptides were synthesized but containing all the P of the original peptide or all the P changed by A.
- Figure 13 shows the reactivity obtained when facing the collection of peptides presented in Figure 12 to the monoclonal antibody anti-polysaccharide B.
- Figure 14 shows the reactivity with the antibody monoclonal anti-polysaccharide B of peptides based on the NMGBPS1 sequence, in which the change Wi 0 for Fi 0 was introduced , and additionally changes in P 7 for A 7 or in Ps for As.
- Figure 10 shows the sequences of the synthesized peptides. 86% of the reactivity with the antibody, with respect to the NMGBPS1 peptide, was retained in the peptide where P 7 was substituted by A 7, when W-io was replaced by Fio (peptide 2, Figure 14). The sequences corresponding to the peptides shown at the bottom of bars 2, 3 and 4 of Figure 14 are shown in the sequence list as SeqID 27, SeqID 28 and SeqID 29.
- Example 16 Synthesis of peptides containing several copies of the sequence necessary for the binding of the anti-polysaccharide B monoclonal antibody to the NMGBPS1-4 peptides.
- the peptides were synthesized and ELISAs were performed where the ability of the new peptides, with respect to the original peptides, to inhibit the binding of the anti-polysaccharide monoclonal antibody B to the polysaccharide B of the meningococcus was evaluated.
- the polystyrene plates were coated with a solution of polysaccharide B purified from the bacterium and mixtures of the anti-polysaccharide B monoclonal antibody were added, at a fixed concentration (5ug / ml), with solutions of different concentrations of the peptides.
- Figure 15 shows the results obtained with the multicopy peptide synthesized from the repetition 3 times of the sequence necessary for the binding of the anti-polysaccharide B monoclonal antibody to the NMGBPS1 peptide.
- the multicopy peptide was able to inhibit the binding of the anti-polysaccharide B monoclonal antibody to polysaccharide B more effectively than the NMGBPS1 peptide.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002634067A CA2634067A1 (en) | 2005-12-29 | 2006-12-28 | Carbohydrate-mimetic peptides and use thereof in pharmaceutical formulations |
EP06828471A EP1982994A2 (en) | 2005-12-29 | 2006-12-28 | Carbohydrate-mimetic peptides and use thereof in pharmaceutical formulations |
AU2006331226A AU2006331226A1 (en) | 2005-12-29 | 2006-12-28 | Carbohydrate-mimetic peptides and use thereof in pharmaceutical formulations |
MX2008008582A MX2008008582A (es) | 2005-12-29 | 2006-12-28 | Peptidos mimeticos de carbohidratos y su empleo en formulaciones farmaceuticas. |
BRPI0620937-8A BRPI0620937A2 (pt) | 2005-12-29 | 2006-12-28 | peptìdeos de carbohidrato mimético e uso dos mesmos em formulação farmacêuticas |
NO20083301A NO20083301L (no) | 2005-12-29 | 2008-07-28 | Karbohydrat-mimetiske peptider samt anvendelse derav i farmasoytiske sammensetninger |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20050283 | 2005-12-29 | ||
CU2005-0283 | 2005-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007073706A2 true WO2007073706A2 (es) | 2007-07-05 |
WO2007073706A3 WO2007073706A3 (es) | 2007-09-13 |
Family
ID=37946113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2006/000020 WO2007073706A2 (es) | 2005-12-29 | 2006-12-28 | Péptidos miméticos de carbohidratos y su empleo en formulaciones farmacéuticas |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1982994A2 (es) |
KR (1) | KR20080090477A (es) |
CN (1) | CN101389643A (es) |
AR (1) | AR058736A1 (es) |
AU (1) | AU2006331226A1 (es) |
BR (1) | BRPI0620937A2 (es) |
CA (1) | CA2634067A1 (es) |
MX (1) | MX2008008582A (es) |
NO (1) | NO20083301L (es) |
WO (1) | WO2007073706A2 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007144771A3 (en) * | 2006-06-15 | 2008-05-22 | Teti Giuseppe | Peptides that mimic non-human cross-reactive protective epitopes of the group b meningococcal capsular polysaccharide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6642354B2 (en) | 1996-08-27 | 2003-11-04 | Chiron Corporation | Molecular mimetics of unique Neisseria meningitidis serogroup B epitopes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU602483B2 (en) * | 1985-01-18 | 1990-10-18 | Immunetech Pharmaceuticals | Immunoregulatory peptides |
ES2319939T3 (es) * | 1997-08-27 | 2009-05-14 | Novartis Vaccines And Diagnostics, Inc. | Mimeticos moleculares de epitopos de meningococos b. |
GB0024200D0 (en) * | 2000-10-03 | 2000-11-15 | Smithkline Beecham Sa | Component vaccine |
-
2006
- 2006-12-26 AR ARP060105778A patent/AR058736A1/es unknown
- 2006-12-28 WO PCT/CU2006/000020 patent/WO2007073706A2/es active Application Filing
- 2006-12-28 CN CNA2006800534515A patent/CN101389643A/zh active Pending
- 2006-12-28 CA CA002634067A patent/CA2634067A1/en not_active Abandoned
- 2006-12-28 EP EP06828471A patent/EP1982994A2/en not_active Withdrawn
- 2006-12-28 MX MX2008008582A patent/MX2008008582A/es unknown
- 2006-12-28 BR BRPI0620937-8A patent/BRPI0620937A2/pt not_active Application Discontinuation
- 2006-12-28 AU AU2006331226A patent/AU2006331226A1/en not_active Abandoned
- 2006-12-28 KR KR1020087018521A patent/KR20080090477A/ko not_active Application Discontinuation
-
2008
- 2008-07-28 NO NO20083301A patent/NO20083301L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6642354B2 (en) | 1996-08-27 | 2003-11-04 | Chiron Corporation | Molecular mimetics of unique Neisseria meningitidis serogroup B epitopes |
Non-Patent Citations (81)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007144771A3 (en) * | 2006-06-15 | 2008-05-22 | Teti Giuseppe | Peptides that mimic non-human cross-reactive protective epitopes of the group b meningococcal capsular polysaccharide |
US8034349B2 (en) | 2006-06-15 | 2011-10-11 | Giuseppe Teti | Peptides that mimic non-human cross-reactive protective epitopes of the group B meningococcal capsular polysaccharide |
Also Published As
Publication number | Publication date |
---|---|
MX2008008582A (es) | 2008-09-26 |
NO20083301L (no) | 2008-09-26 |
AU2006331226A1 (en) | 2007-07-05 |
WO2007073706A3 (es) | 2007-09-13 |
CN101389643A (zh) | 2009-03-18 |
AR058736A1 (es) | 2008-02-20 |
BRPI0620937A2 (pt) | 2011-11-29 |
EP1982994A2 (en) | 2008-10-22 |
CA2634067A1 (en) | 2007-07-05 |
KR20080090477A (ko) | 2008-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4827196B2 (ja) | 髄膜炎菌類タンパク質nmb1870のドメインおよびエピトープ | |
ES2557282T3 (es) | Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso | |
JP7271654B2 (ja) | 改変された髄膜炎菌fHbpポリペプチド | |
JP2008538183A (ja) | B型インフルエンザ菌 | |
JP2012000112A (ja) | 型分類不能なHaemophilusinfluenzae由来のポリペプチド | |
JP2016190869A (ja) | 複数の髄膜炎菌血清群に対する注射可能ワクチン | |
JP2007533729A (ja) | タンパク質を使用する髄膜炎菌の血清群yに対する免疫 | |
ES2847923T3 (es) | Vacunas contra el meningococo del serogrupo X | |
EA038940B1 (ru) | Менингококковые вакцины | |
ES2478010T3 (es) | Péptidos que imitan epítopos protectores sin reactividad cruzada en seres humanos del polisacárido capsular de meningococo del grupo B | |
WO2007073706A2 (es) | Péptidos miméticos de carbohidratos y su empleo en formulaciones farmacéuticas | |
BRPI0710064A2 (pt) | composição farmacêutica contendo a proteìna nmb0938 | |
RU2773464C1 (ru) | Модифицированный белок, связывающий фактор н | |
WO2005054282A1 (es) | Proteína nmb0928 y su uso en formulaciones farmaceuticas | |
EA046480B1 (ru) | МОДИФИЦИРОВАННЫЕ ПОЛИПЕПТИДЫ МЕНИНГОКОККОВОГО fHbp | |
ES2334138T3 (es) | Proteina nmb1125 y uso de la misma en formulaciones farmaceuticas. | |
WO2009000217A1 (es) | Composición farmacéutica que comprende la proteína nmb1796 | |
BRPI0709922A2 (pt) | composiÇço farmacÊutica contendo a proteÍna nmb0606 | |
KR20080081198A (ko) | 단백질 nma0939를 포함하는 약학적 조성물 | |
WO2007087758A2 (es) | Mimotopos de polisacáridos capsulares de neisseria meningitidis y formulaciones farmacéuticas | |
Neri et al. | A Novel Mimetic Antigen Eliciting Protective | |
WO2009056075A1 (es) | Composición farmacéutica que comprende la proteína nmb0873 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2634067 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008582 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006331226 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3755/CHENP/2008 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2006331226 Country of ref document: AU Date of ref document: 20061228 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 570016 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2006331226 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087018521 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006828471 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680053451.5 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: PI0620937 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080630 |